Skip to content

Safety and efficay assessment of translocator protein (TSPO) ligand [C-11]CB184 in healthy volunteers.

Safety and efficay assessment of translocator protein (TSPO) ligand [C-11]CB184 in healthy volunteers. - First-in-human study of [C-11] CB184.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000020139
Enrollment
15
Registered
2015-12-10
Start date
2015-12-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteer

Interventions

Sponsors

Tokoyo Metropolitan Institute of Gerontology
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. The subject who has intention to participate in this study, and signed informed consent. 2. Male subject of >=20 and =<60 years old. 3. The subject who judged by clinical investigator by means of physical examination and laboratory tests to be eligible as a participant in this study.

Exclusion criteria

Exclusion criteria: 1. The subject who has dysfunction in the liver / kidney. 2. The subject who has abnormal findings in the central nervous system. 3. The subject having cardiac failure. 4. The subject with a history of a drug or food allergy. 5. The subject who juddged by the clinical investigator to be inappropriate as a participant in this study.

Design outcomes

Primary

MeasureTime frame
Safety: Adverse Drug Reaction (symptoms, blood pressure, respiratory rate, heart rate, general blood tests) Efficacy: Quality and analyzability of PET/CT image. Dosimetry Date of evaluation: on the day and one week after the PET scanning

Countries

Japan

Contacts

Public ContactKenji Ishii

Tokoyo Metropolitan Institute of Gerontology Research Team for Neuroimaging

ishii@pet.tmig.or.jp03-3964-3241

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026